Evidence map›Paper›PMID 40917513›Full record

ArticleMaterials today. Bio2025

Oral targeting tilianin nanoplatform mitigates atherosclerosis through promoting macrophage phagocytosis and anti-inflammation.

Min Sun, Mengran Guo, Zhongshan He, Yaoyao Luo, Huiling Yang, Yupei Zhang, Yuntao Gao, Xuli Ruan, Ruyue Liu, Jingrun Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Min SunDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Mengran GuoDepartment of Critical Care Medicine, Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610000, China.
Zhongshan HeDepartment of Critical Care Medicine, Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610000, China.
Yaoyao LuoDepartment of Critical Care Medicine, Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610000, China.
Huiling YangSchool of Pharmacy, Shihezi University, Shihezi, 832008, China.
Yupei ZhangDepartment of Critical Care Medicine, Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610000, China.
Yuntao GaoDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Xuli RuanDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Ruyue LiuDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Jingrun LiDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Wenjiang CaoDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Chuansheng HuangDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Liping WangDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Yong YuanDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.
Xiangrong SongDepartment of Critical Care Medicine, Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610000, China.
Xinchun WangDepartment of Pharmacy, First Affiliated Hospital, Shihezi University, Shihezi, 832008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modulating macrophage function is an effective strategy for treating atherosclerosis. Our previous research shows that tilianin (Til) effectively regulates macrophage polarization. This immune modulation positions Til as a promising plant-derived therapeutic agent with potential for atherosclerosis treatment and management. Due to its biopharmaceutics classification system (BCS) IV drug properties, it is a challenge to delivering Til to macrophages in atherosclerotic plaques, especially via the oral route. Herein, we introduced a folate-modified oral Til nanocrystal liposome (FA-Lipo@Til NCs) that showed enhanced mucus permeability and transmembrane transport ability across the intestinal epithelium. It could subsequently target and accumulate in macrophages within aortic plaques. After three months of oral treatment with FA-Lipo@Til NCs in apolipoprotein E deficient (

Indexed as

AtherosclerosisFolateNanocrystal liposomesOral targetingTilianin

Identifiers

PMID40917513
PMCPMC12408410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.